DEL-22379 - ERK 抑制劑 - 生命科學(xué)試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEDEL-22379Cat. No.: HY-18932CAS No.: 181223-80-3分式: CHNO分量: 444.53作靶點(diǎn): ERK作通路: MAPK/ERK Pathway; Stem Cell/Wnt儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 30 mg/mL (67.49 mM)* means solub

2、le, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.2496 mL 11.2478 mL 22.4957 mL5 mM 0.4499 mL 2.2496 mL 4.4991 mL10 mM 0.2250 mL 1.1248 mL 2.2496 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 DEL-22379種 ERK 聚化抑制劑。DEL-22379 易與 ERK2 結(jié)合，Kd 為低微 爾平，即使在

3、低納摩爾濃度下也可檢測到 EL-22379 與 ERK2 結(jié)合。DEL-22379 抑制 ERK2 聚化，IC50 約為 0.5 M。IC50 & Target ERK20.5 M (IC50)1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE體外研究 DEL-22379 is an ERK dimerization inhibitor. DEL-22379 abolishes EGF-induced co-immunoprecipitation ofectopic ERK2 molecules tagged with hemagglutinin

4、 (HA) or FLAG epitopes, with an estimated half-maximalinhibitory concentration (IC50) of 0.5 M. DEL-22379 inhibits growth of tumor cells harboring RAS-ERKpathway oncogenes. The biological effects of DEL-22379 are investigated on tumor cells in culture. Thecytostatic effects of DEL-22379 are compared

5、 to those of the MEK inhibitor PD-0325901 and the ERK kinaseinhibitor SCH-772984, as reflected by their half-maximal growth inhibitory concentrations (GI50). Cell linesharboring mutant BRAF are the most sensitive to the three compounds. In comparison, wild-type (WT) celllines for BRAF and RAS are th

6、e most resistant, and RAS mutant cells exhibit a range of sensitivities. In cellsshowing different oncogenic genotypes, distinct sensitivity to DEL-22379 can not be attributed to variationson its effects on dimerization, because DEL-22379 displays similar dimerization- and cytoplasmic signaling-inhi

7、bitory dose responses (IC50 of 150-400 nM) regardless of the genotype 1.體內(nèi)研究 To test DEL-22379 antitumor effects, some of the aforementioned cell lines are xenografted into nude mice,and tumor growth is monitored after intra-peritoneal administration of DEL-22379 at 15 mg/kg. At such adose, inhibiti

8、on of ERK dimerization is evident in liver extracts and in xenografted tumors. DEL-22379markedly inhibits tumor progression for A375 cells (BRAF mutant) 1.PROTOCOLCell Assay 1 HEK293T cells are plated at a density of 1,000-2,000 cells/well and treated with DEL-22379 (0.2-1 M) for48 hr, Alamar Blue i

9、s added, and the colorimetric change is measured at 570 and 600 nm. GI50 is estimatedby nonlinear regression using GraphPad5 Prism Software. Apoptosis is analyzed by evaluating caspase 3activity, either by western blotting or using the Caspase-Glo 3/7 luminogenic assay 1.MCE has not independently co

10、nfirmed the accuracy of these methods. They are for reference only.Animal Mice 1Administration 1 Cancer cells are xenografted in female, athymic nu/nu mice of 8 weeks of age. 3106 cells are injectedsubcutaneously in the lateral flank and allowed to develop for 10-15 days before treatment with DEL-22

11、379at 15 mg/kg every 12 hr for 2 weeks. patient-derived xenografts (PDXs) are performed using patient-derivedcolorectal cancer cells harboring BRAFV600E from non-necrotic areas of primary adenocarcinomas frompatients that undergo surgical resection. Cells are grafted in both flanks or in the cecum o

12、f NOD-SCID mice.DEL-22379 is administered by intra-peritoneal injection at a concentration of 15 mg/kg every 12 hr for 30days 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Herrero A, et al. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Cancer Cell.2015 Aug 10;28(2):170-82.McePdfHeightCauti